Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Jun 26;2(12):1382-1385.
doi: 10.1182/bloodadvances.2018018093.

Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL

Matthias Wölfl  1 , Mareike Rasche  2 , Matthias Eyrich  1 , Renate Schmid  1 , Dirk Reinhardt  2 , Paul G Schlegel  1
Affiliations
Case Reports

Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL

Matthias Wölfl et al. Blood Adv. .

Abstract

  1. A case of MLL-rearranged leukemia that rapidly adapts to immunological stimuli illustrating the high plasticity of this phenotype.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: P.G.S. is a principal investigator of the early access program for blinatumomab in refractory or relapsed pediatric ALL (RIALTO; sponsor: Amgen). The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Phenotypic evolution of leukemic blasts after blinatumomab treatment. (A) L1/2 morphology of blasts (bone marrow) at the time of relapse, before blinatumomab (i); myelomonocytic morphology of cells in the bone marrow 11 days after blinatumomab treatment (ii) and 9 days after cessation of blinatumomab (iii). In each image pair, magnification is 1:1000 (left) and 1:500 (right) (Pappenheim staining). (B) Flow cytometry at the 2 respective time points: directly after blinatumomab treatment (left 2 columns) and 9 days later (right 2 columns). Staining shows CD45+ live cells.
See this image and copyright information in PMC

References

    1. Driessen EM, de Lorenzo P, Campbell M, et al. . Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol. Leukemia. 2016;30(5):1184-1187. - PubMed
    1. Guest EM, Stam RW. Updates in the biology and therapy for infant acute lymphoblastic leukemia. Curr Opin Pediatr. 2017;29(1):20-26. - PubMed
    1. Sotillo E, Barrett DM, Black KL, et al. . Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5(12):1282-1295. - PMC - PubMed
    1. Mejstríková E, Hrusak O, Borowitz MJ, et al. . CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment. Blood Cancer J. 2017;7(12):659. - PMC - PubMed
    1. Jacoby E, Nguyen SM, Fountaine TJ, et al. . CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun. 2016;7:12320. - PMC - PubMed

Publication types

MeSH terms